Publications
Journals
Maynard S, Ros-Soto J, Chaidos A, et al. , 2021, The role of ibrutinib in COVID-19 hyperinflammation: a case report, International Journal of Infectious Diseases, Vol:105, ISSN:1201-9712, Pages:274-276
Claudiani S, Apperley JF, Deplano S, et al. , 2016, Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia, American Journal of Hematology, Vol:91, ISSN:1096-8652, Pages:E480-E481
Neelakantan P, Rezvani K, May P, et al. , 2014, Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects, British Journal of Haematology, Vol:164, ISSN:0007-1048, Pages:608-610
Milojkovic D, Apperley J, 2008, State-of-the-art in the treatment of chronic myeloid leukaemia, Current Opinion in Oncology, Vol:20, ISSN:1040-8746, Pages:112-121
De Melo VA, Milojkovic D, Khorashad JS, et al. , 2007, Philadelphia-negative clonal haematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukaemia, Blood, Vol:110, Pages:3086-3087